Esphera SynBio Announces New Project to Advance Next Generation mRNA Vaccine Development, supported by the CQDM Quantum Leap program
Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing next-generation mRNA vaccines. Using its proprietary technology, Esphera SynBio causes ...
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
FMC-220 is a first-in-class covalent activator of p53Y220Cdesigned to address potency and tolerability challenges of non-covalent approachesIn ...
Joplin Globe2d
ProteinQure Strengthens Leadership Team with Key Appointments to Accelerate Translational and Clinical Development Programs
TORONTO, ON / ACCESSWIRE / / ProteinQure, a leader in computational peptide design, is proud to announce the addition of two ...
Will AI revolutionize drug development? Researchers explain why it depends on how it’s used
Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...